Holen Sie sich die Stockscreener-App
3.32
6.75%
0.21
Handel nachbörslich:
3.32
Agenus Inc Aktie (AGEN) Neueste Nachrichten
How Agenus' Pipeline Progress Unlock Its Next Growth Phase - TradingView
Agenus: Weighing The Clinical Progress Against The Company's Cash (NASDAQ:AGEN) - Seeking Alpha
BOT+BAL Demonstrates Durable Immune Benefit in Advanced Melanoma – Agenus - Oncodaily
Agenus reports melanoma trial data for checkpoint therapy By Investing.com - Investing.com South Africa
AGEN News | AGENUS INC (NASDAQ:AGEN) - ChartMill
Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026 - BioSpace
AI model identifies colorectal cancer patients likely to respond - Investing.com UK
Agenus reports melanoma trial data for checkpoint therapy - Investing.com UK
Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC - 01net
New melanoma drug combo sees 42% of patients alive at 2 years - Stock Titan
AGEN Stock Dips 19.4% in a Month: Time to Buy, Hold or Sell? - TradingView
AGEN Technical Analysis | Trend, Signals & Chart Patterns | AGENUS INC (NASDAQ:AGEN) - ChartMill
Agenus (AGEN) chief takes 4,540 common shares as salary - Stock Titan
Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer - BioSpace
Agenus (AGEN) price target decreased by 32.61% to 15.81 - MSN
Are options traders betting on a big move in Agenus stock? - MSN
Agenus Inc.Common Stock (NQ: AGEN - FinancialContent
Agenus (AGEN) Reports Phase 1b Results for Innovative Cancer Tre - GuruFocus
Agenus reports phase 1b liver cancer trial results - Investing.com UK
Agenus announces publication of Phase 1b BOT+BAL data - TipRanks
Agenus reports phase 1b liver cancer trial results By Investing.com - Investing.com Nigeria
Agenus Announces Resignation of Principal Accounting Officer - TipRanks
Agenus Announces Publication of Phase 1b Botensilimab and Balstil - The National Law Review
Early drug combo yields responses in liver cancer after immunotherapy - Stock Titan
Agenus (AGEN) Principal Accounting Officer Austin Charette plans May 2026 exit - Stock Titan
Advancing Strategies to Activate and Sustain Immune Response in Harder-to-Treat CancersAgenus - Oncodaily
Agenus (AGEN) Q1 Earnings and Revenues Miss Estimates - Yahoo Finance
Agenus Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Is Agenus (AGEN) Undervalued After Q1 2026? Revenue $33.7M (miss - GuruFocus
Agenus (AGEN) Releases Q1 2026 Earnings: Revenue Growth but EPS Miss - Quiver Quantitative
MSN Money - MSN
Agenus: Q1 Earnings Snapshot - WKYC
AGENUS INC 1Q 2026: Revenue $33.7M, EPS $1.02— 10-Q Summary - TradingView
[10-Q] AGENUS INC Quarterly Earnings Report - Stock Titan
Agenus Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Agenus (AGEN) Marks Significant Progress in Q1 2026 - GuruFocus
Agenus (AGEN) Cleared of SEC Investigation and Court Dismisses S - GuruFocus
Agenus reports Q1 results, Phase 3 trial enrollment begins By Investing.com - Investing.com South Africa
Agenus (AGEN) Reports Significant Increase in Cash Reserves - GuruFocus
Agenus reports Q1 results, Phase 3 trial enrollment begins - Investing.com
Immuno-oncology developer Agenus' Q1 revenue rises, posts profit - TradingView
Zydus collaboration lifts Agenus (Nasdaq: AGEN) to Q1 2026 profit - Stock Titan
Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development - marketscreener.com
Number of shareholders of Agenus Inc. – NASDAQ:AGEN - TradingView
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):